Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK cells + nogapendekin alfa
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
NK cells + nogapendekin alfa is an investigational combination immunotherapy consisting of adoptively transferred universal donor (non-HLA matched) natural killer (NK) cells and the interleukin-15 (IL-15) superagonist ALT-803 (nogapendekin alfa). ALT-803 is a recombinant fusion protein complex designed to mimic the biological activity of IL-15 trans-presentation; it consists of an IL-15 mutant (N72D) with increased biological activity, bound to the sushi domain of the IL-15 receptor alpha (IL-15Rα) and fused to a human IgG1 Fc domain. This structure enhances the half-life and potency of the cytokine. In clinical trials led by Brenda Cooper, MD, ALT-803 is administered following NK cell infusion to support the survival, expansion, and anti-tumor cytotoxicity of the donor cells. The combination is being evaluated for the treatment of various refractory hematologic malignancies, such as acute myeloid leukemia and multiple myeloma, as well as advanced solid tumors including colon carcinoma and sarcomas.
- Brand names
- Anktiva
- Other names
- nogapendekin alfa inbakiceptnogapendekin alfa-n72d-tgpUniversal Donor NK Cell Therapy + ALT-803
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on NK cells + nogapendekin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK cells + nogapendekin alfa.